Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases

Pharmacology and Therapeutics

Volumn 76, Issue 1-3, 1997, Pages 55-71

  Showalter, H D Hollis ^a   Kraker, Alan J ^a  

^a PFIZER INC   (United States)

Author keywords

Fibroblast growth factor receptor (FGFr) tyrosine kinase; Phosphorylation; Platelet derived growth factor receptor (PDGFr) tyrosine kinase; Small molecule inhibitors; Src family tyrosine kinases

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ALPHA (3,4 DIMETHOXYBENZYLIDENE) 2 PYRIDYLACETONITRILE; ANGELMICIN B; BENZOPYRAN DERIVATIVE; C 292; DAMNACANTHAL; FIBROBLAST GROWTH FACTOR RECEPTOR; G 25; GELDANAMYCIN; HERBIMYCIN A; HYPERICIN; IMATINIB; INDOLE DERIVATIVE; LEFLUNOMIDE; N [4 METHYL 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]PHENYL]BENZAMIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; RADICICOL; RG 50875; TERIFLUNOMIDE; THIOL REAGENT; TRAPIDIL; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WIN 41662; WIN 61651;

CANCER; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIVISION; ENZYME INHIBITORS; HUMANS; NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SRC-FAMILY KINASES;

EID: 0031277578     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)00097-1     Document Type: Review

References (88)

1. Ahn, S. C., Kim, B. Y., Park, C. S., Lee, H. S., Suh, P. G., Ryu, S. H., Rho, H. M., Rhee, J. S., Mheen, T. I. and Ahn, J. S. (1995) Inhibition of PDGF-induced phosphoinositide-turnover by glucopiericidin A. Biochem. Mol. Biol. Int. 57: 125-132.
2. Alonso, G., Koegl, M., Mazurenko, N. and Courtneidge, S. A. (1995) Sequence requirements for binding of src family tyrosine kinases to activated growth factor receptors. J. Biol. Chem. 270: 9840-9848.
3. Bando, K., Kannuki, S., Rokutan, K., Shouno, M. and Matsumoto, K. (1995) Effects of trapidil and suramin on growth factor induced calcium response and tyrosine phosphorylation in human glioma cells. Neurol. Med. Chir. (Tokyo) 35: 631-638.
4. Bilder, G. E. and Rojas, C. (1996) Inhibitors of the platelet-derived growth factor receptor tyrosine kinase. J. Cardiovasc. Drug Rev. 14: 380-399.
5. Blankley, C. J., Boschelli, D. H., Doherty, A. M., Hamby, J. M., Klutchko, S. and Panek, R. L. (1996a) Pyrido[2,3-d]pyrimidines as protein tyrosine kinase-mediated cell proliferation inhibitors. World Patent Application WO 9634867, November 7.
6. Blankley, C. J., Doherty, A. M., Hamby, J. M., Panek, R. L., Schroeder, M. C., Showalter, H. D. H. and Connolly, C. (1996b) 6-Aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase-mediated cellular proliferation. World Patent Application WO 9615128, May 23.
7. Bolen, J. B., Penhallow, R. C. and Burkhardt, A. L. (1997) Signal transduction by the src family of tyrosine protein kinases. In: Encyclopedia of Cancer, pp. 1657-1668, Bertino, J. (ed.) Academic Press, San Diego.
8. Bornfeldt, K. E. (1996) Intracellular signaling in arterial smooth muscle migration versus proliferation. Trends Cardiovasc. Med. 6: 143-151.
9. Buchdunger, E., Zimmermann, J., Mett, H. Meyer, T., Mueller, M., Regenass, U. and Lydon, N. B. (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA 92: 2553-2562.
10. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Mueller, M., Druker, B. J. and Lydon, N. B. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.Cancer Res. 56: 100-104.
11. Chanmugam, P., Feng, L., Liou, S., Jang, B. C., Boudrean, M., Yi, G., Lee, J. H., Kwon, H. J., Beppu, T., Yoshida, M., Xia, Y., Wilson, C. B. and Hwang, D. (1995) Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipo-polysaccharide and in experimental glomerulonephritis. J. Biol. Chem. 270: 5413-5426.
12. Chen, C. Mattar, S. G., Hughes, J. D., Pierce, G. F., Cock, J. E., Ku, D. N., Hanson, S. R. and Lumsden, A. B. (1996) Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venons anastomotic intimal hyperplasia in the arterinvenous graft. Circulation 94: 1989-1995.
13. Claesson-Welsh, L. (1994) Platelet-derived growth factor receptor signals. J. Biol. Chem. 269: 32023-32026.
14. Dahring, T. K., Lu, G. H., Hamby, J. M., Batley, B. L., Krakerr, A. J. and Panek, R. L. (1997) Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 281: 1446-1456.
15. Dow, R. L. (1996) 5,10-Dihydropyrimido[4,5-b]quinolin 4(1H)-ones tyrosine kinase inhibitors. World Patent Application WO 9628444, September 19.
16. Dow, R. L., Bechle, B. M., Chou, T. T., Goddard, C. and Larson, E. R. (1995) Selective inhibition of the tyrosine kinase pp60src by analogs of 5,10-dihydropyrimido[4,5-b]quinolin-4(1 H)-one. Bioorg. Med. Chem. Lett. 5: 1007-1010.
17. Dow, R. L., Koch, K. and Schulte, G. R. (1997) 4-Aminopyrazolo[3,4-d]pyrimidines and 4-ammopyrazolo[3,4-d]pyridines as tyrosine kinase inhibitors, US Patent 5593997, January 14.
18. Edison, A. M., Barker, S. C., Kassel, D. B., Luther, M. A. and Knight, W. B. (1995) Exploration of the sequence specificity of pp60c-src tyrosine kinase. Minimal peptide sequence required for maximal activity. J. Biol. Chem. 270: 27112-27115.
19. Faltynek, C. R., Schroeder, J., Mauvais, P., Miller, D., Wing, S., Murphy, D, Lehr, R., Kelley, M., Maycock, A., Michne, W., Miski, M. and Thunberg, A. L. (1995a) Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity. Biochemistry 34: 12404-12410.
20. Faltynek, C. R., Wang, S., Miller, D., Mauvais, P., Gauvin, B., Reid, J., Xie, W., Hoekstra, S., Juniewicz, P., Sarup, J., Lehr, R., Sawutz, D. G. and Murphy, D. (1995b) Inhibition of T lymphocyte activation by a novel p56lck tyrosine kinase inhihitor. J. Enzyme Inhib. 9: 111-122.
21. Fredenhagen, A., Mett, H., Meyer, T., Buchdunger, E., Regenass, U., Roggo, R. E. and Petersen, F. (1995) Protein tyrosine kinase and protein kinase C inhibition by fungal anthraquinones related to emodin. J. Antibiot. 48: 1355-1358.
22. Frew, T., Powis, G., Berggren, M., Gallegos, A., Abraham, R. T., Ashendel, C. L., Zalkow, L. H., Hudson, C., Gruszecka-Kowalik, E., Burgess, E. M., Benedetti-Doctorovich, V., Kerrigan, J. E., Lambropoulos, J., Merriman, R. and Bonjouklian, R. (1995) Novel quinone antiproliferame inhibitors of phosphatidylinositol-3-kinase. Anticancer Drug Des. 10: 347-359.
23. Fry, D. W. (1994) Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Expert Opin. Invest. Drugs 3: 577-595.
24. Fry, D. W. and Bridges, A. J. (1995) Inhibitors of protein tyrosine kinases. Curr. Opin. Biotechnol. 6: 662-667.
25. Fry, D. W. and Nelson, J. M. (1995) Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors. Anticancer Drug Des. 10: 607-622.
26. Gastl, G., Hermann, T., Steurer, M., Zmija, J., Gunsilius, E., Unger, C. and Kraft, A. (1997) Angiogenesis as a target for tumor treatment. Oncology 54: 177-184.
27. Gazit, A., App, H., McMahon, G., Chen, J., Levitzki, A. and Bohmer, F. D. (1996) Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxaliues, quinolines, and indole tyrphostins. J. Med. Chem. 39: 2170-2177.
28. Giese, N. A. and Lokker, N. (1996) Method and compositions for inhibiting protein kinases. World Patent Application WO 9613259, May 9.
29. Giese, N. A., Lokker, N., Laibelman, A. M. and Scarborough, R. M. (1996) Pharmaceutical pyrzole compositions useful as inhibitors of protein kinase. World Patent Application WO 9614843, May 23.
30. Golomb, G. and Fishbein, I. (1997) Tyrphostins, inhibitors of protein tyrosine kinase, in restenosis. Adv. Drug Delivery Rev. 24: 51-62.
31. Hamby, J. M., Connolly, C. J. C., Schroeder, M. C., Winters, R. T., Showalter, H. D. H., Panek, R. L., Major, T. C., Olsewski, B., Ryan, M. J., Dahring, T., Lu, G. H., Keiser, J., Amar, A., Shen, C., Kraker, A. J., Slintak, V., Nelson, J. M., Fry, D. W., Bradlord, L., Hallak, H. and Doherty, A. M. (1997) Structure-activity relationships for a novel seties of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. 40: 2296-2303.
32. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A. and Connelly, P. A. (1996) Discovery of a novel, potent, and src family-selective tyrosine kinase inhibitor. Study of lck- and fynT-dependent T-cell activation. J. Biol. Chem. 271: 695-701.
33. Heldin, C.-H. and Westermark, B. (1991) Platelet-derived growth factor and autocrine mechanisms of oncogenic processes. Crit. Rev. Oncol. 2: 109-124.
34. Hirth, K. P., Schwartz, D. P., Mann, E., Shawver, L. K., Keri, G., Szckely, I., Bajor, T., Haimichael, J., Orfi, L., Levitzki, A., Gazit, A., Ullrich, A., Lammers, R., Kabbinavar, F. F., Slamon, D. J. and Tang, C. P. (1995) Treatment of platelet-derived growth factor-related disorders such as cancers using inhibitors of platelet-derived growth receptor. World Patent Application WO 9519169, July 20.
35. Hori, H., Higashi, K., Ishiyama, T., Uramoto, M., Uehara, Y. and Oki, T. (1996) Structure of angelmicin B, a novel src signal transduction inhibitor. Tetrahedron Lett. 37: 2785-2788.
36. Huang, C.-K. (1996) 2-Iminochromene derivatives as inhibitors of protein tyrosine kinase. World Patent Application WO 9640670, December 19.
37. Huang, C.-K., Wu, F.-Y. and Ai, Y.-X. (1995) Polyhydroxylated 3-(N-phenyl) carbamoyl-2-iminochromene derivatives as potent: inhibitors of tyrosine kinase p60c-src. Bioorg. Med. Chem. Lett. 5: 2423-2428.
38. Jackson, C. L. and Schwartz, S. M. (1992) Pharmacology of smooth muscle cell replication. Hypertension (Dallas) 20: 713-736.
39. Kelloff, G. J., Fay, J. R., Steele, V. E., Lubet, R. A., Boone, C. W., Crowell, J. A. and Sigman, C. C. (1996) Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev. 5: 657-666.
40. Kil, K.-S., Yum, Y.-N., Seo, S.-H. and Lee K.-T. (1996) Antitumor activities of hypericin as a protein tyrosine kinase blocker. Arch. Pharmacal Res. 19: 490-496.
41. Kovalenko, M., Roennstrand, L., Heldin, C.-H., Loubtchenkov, M., Gazit, A., Levitzki, A. and Boehmer, F. D. (1997) Phosphorylation site-specific inhibition of platelet-derived growth factor β-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry 36: 6260-6269.
42. Kown, H. J., Yoshida, M., Fukui, Y., Horinouchi, S. and Beppu, T. (1992) Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res. 52: 6926-6930.
43. Levitzki, A. (1996) Src as a target for anticancer drugs. Anticancer Drug Des. 11: 175-182.
44. Lindner, V. and Reidy, M. A. (1993) Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. Circ. Res. 73: 589-595.
45. Lindner, V., Giachelli, C. M., Schwartz, S. M. and Reidy, M. A. (1995) A subpopulation of smooth muscle cells in injured rat arteries expresses platelet-derived growth factor-B chain mRNA. Circ. Res. 76: 951-957.
46. Liu, M., Liu, J., Buch, S., Tanswell, A. K. and Post, M. (1995) Antisense oligonucleotides for PDGF-B and its receptor inhibit mechanical strain-induced fetal lung cell growth. Can. Am. J. Physiol. 269: L178-L184.
47. Lou, Q., Leftwich, M. E. and Lam, K. S. (1996) Identification of GIYWHHY as a novel peptide substrate for human p60c-src protein tyrosine kinase. Bioorg. Med. Chem. 4: 677-682.
48. Lou, Q., Leftwich, M. E., McKay, R. T., Salmon, S. E., Rychetsky, L. and Lam, K. S. (1997) Potent pseudosubstrate-based peptide inhibitors for p60c-src protein tyrosine kinase. Cancer Res. 57: 1877-1881.
49. Mattar, S. G., Hanson, S. R., Pierce, G. F., Chen, C., Hughes, J. D., Cook, J. E., Shen, C., Noe, B. A., Suwyn, C. R., Scott, J. R. and Lumsden, A. B. (1996) Local infusion of FGF-saporin reduces intimal hyperplasia. J. Surg. Res. 60: 339-344.
50. Mattar, T., Kochhar, K., Bartlett, R., Bremer, E. G. and Finnegan, A. (1993) Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 334: 161-164.
51. McLeod, H. L., Brunton, V. G., Eckardt, N., Lear, M. J., Robins, D. J., Workman, P. and Graham, M. A. (1996) In vivo pharmacology and antitumor evaluation of the tyrpbostin tyrosine kinase inhibitor RG13022. Br. J. Cancer 74: 1714-1718.
52. Miller. D., Wang, S., Reid, J., Xie, W., Gauvin, B., Kelley, M., Sarup, J., Sawutz, D. G., Miski, M., Dolle, R. E. and Faltynek, C. R. (1995) Approach to the discovery of novel, selective inhibitors of p56lck tyrosine kinase: identification of non-hydroxylated chrornones as p56lck inhibitors. Drug Dev. Res. 34: 344-352.
53. Missbach, M. (1996) Pyrrolo[2,3-d]pyrimidines and their use. World Patent Application WO 9610028, April 4.
54. c-src inhibit bone resorption in vitro. J. Bone Miner. Res. 11: S398.
55. Miyaji, K., Tani, E., Nakano, A., Ikemoto, H. and Kaba, K. (1995) Inhibition by 5′-methylthiondenosine of cell growth and tyrosine kinase activity stimulated by fibroblast growth factor receptor in human gliomas. J. Neurosurg. 83: 690-697.
56. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R. and Schlessinger, J. (1997) Structure of the tyrosine kinase domain of fibroblast factor receptor in complex with inhibitors. Science 276: 955-960.
57. Myers, M. R., Persons, P. E., Ly, C. Q. and Spada, A. P. (1995) Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase. US Patent 5476851, December 19.
58. Myers, M. R, Setzer, N. N., Spada, A. P., Zulli, A. L., Hsu, C.-Y. J., Zilberstein, A., Johnson, S. E., Hook, L. H. and Jacoski, M. V. (1997) The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p56lck and EGF-R tyrosine kinase activity. Bioorg. Med. Chem. Lett. 7: 417-420.
59. c-src identified using a random 15-amino-acid peptide library. FEBS Lett. 399: 237-240.
60. Ochs, H. D. (1996) The molecular basis of primary immunodeficiency disorders. In: Intravenous Immumonoglobulin Research and Therapy, Proceedings of the Fourth International Symposium on Intravenous Immunoglobulin Therapy, Interlaken, Switzerland, June 1996, pp. 175-191, Kazatchkine, M. D. and Morell, A. (eds.) Parthenon Publishiny, New York.
61. Palmer, B. D., Rewcastle, G. W., Thompson, A. M., Boyd, M., Showalter, H. D. H., Sercel, A. D., Fry, D. W., Kraker, A. J. and Denny, W. A. (1995) Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2′-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases. J. Med. Chem. 38: 58-67.
62. Panek, R. L., Lu, G. H., Klutchko, S. R., Batley, B. L., Dahring, T. K., Hamby, J. M., Hallak, H., Doherty, A. M. and Keiser, J. A. (1997) In vitro pharmacological characterization of PD 166285, a new broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther., in press.
63. Patrick, D. R. and Heimbrook, D. C. (1996) Protein kinase inhibitors for the treatment of cancer. Drug Discov. Today 1: 325-330.
64. Pillay, L, Nakano, H. and Sharma, S. V. (1996) Radicicol inhibits tyrosine phosphorylation of the antotic src substrate Sam68 and retards subsequent exit from antosis of src-transformed cells. Cell Growth Differ. 7: 1487-1499.
65. Reidy, M. A. and Bendeck, M. P. (1997) The development of arterial lesions: a process controlled by multiple factors. Fundam. Clin. Cardiol. 28: 55-67.
66. Ross, R., Raines, E. W. and Bowen-Pope, D. F. (1986) The biology of platelet-derived growth factor. Cell 46: 155-169.
67. Saltiel, A. R. (1995) Signal transduction pathways as drug targets. Sci. Am. Sci. Med. 2: 58-67.
68. Sawutz, D. G., Bode, D. C., Briggs, M., Reid, J. R., Canniff, P., Caldwell, L., Faltynek, C. R., Miller, D., Dunn, J. A., de Garavilla, L., Guiles, J. W., Weigelt, C., Michne, W., Treasurywala, A. M. and Silver, P. J. (1996) In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors. Biochem. Pharmacol. 51: 1631-1638.
69. Shimokado, K., Umezawa, K. and Ogata, J. (1995) Tyrosine kinase inhibitors inhibit multiple steps of the cell cycle of vascular smooth muscle cells. Exp. Cell Re. 220: 266-273.
70. Showalter, H. D. H., Sercel, A. D., Leja, B. M., Wolfangel, C. D., Ambroso, L. A., Elliott, W. L., Fry, D. W., Kraker, A. J., Howard, C. T., Lu, G. H., Moore, C. W., Nelson, J. M., Roberts, B. I., Vincent, P. W., Denny, W. A. and Thompson, A. M. (1997) Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2′-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners. J. Med. Chem. 40: 413-426.
71. Shugar, D. (1995) Protein kinase inhibitors - potential chemotherapeuttc agents. Acta Biochim. Pol. 42: 405-418
72. Sicheri, F., Moarefi, I. and Kuriyan, J. (1997) Crystal structure of the src family tyrosine kinase hck. Nature 385: 602-609.
73. Soriano, P., Montgomery, C., Geske, R. and Bradley, A. (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693-702.
74. Spada, A. P. and Myers, M. R. (1995) Small molecule inhibitors of tyrosine kinase activity. Expert Opin. Ther. Pat. 5: 805-817.
75. c-src in progressive stages of human colorectal cancer. J. Clin. Invest. 91: 51-60.
76. Twamley-Stein, G. M., Pepperkok, R., Ansorge, W. and Courtneidge, S. A. (1993) The src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 90: 7696-7700.
77. Uckun, F. M. (1996) Immunoconjugates comprising tyrosine kinase inhibitors. World Patent Application WO9606116, February 29.
78. Uehara, Y., Li, P.-M., Fukazawa, H., Mizuno, S., Nihei, Y., Nishio, M., Hanada, M., Yamamoto, C., Furumai, T. and Oki, T. (1993) Angelmicins, new inhibitors of oncogenic src signal transduction. J. Antibiot. 46: 1306-1308.
79. Wang, W., Chen, H. J., Schwartz, A., Cannon, P. J., Stein, C. A. and Rabbani, L. E. (1996) Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides. J. Clin. Invest. 98: 443-450.
80. Weemink, P. A. O. Verheul, E., Kerkhof, E., van Veelen, C. W. M. and Rijksen, G. (1996) Inhibitors of protein tyrosine phosphorylation reduce the proliferation of two human glioma cell lines. Neurosurgery 38: 108-114.
81. Xu, W., Harrison, S. C. and Eck, M. J. (1997) Three-dimensional structure of the tyrosine kinase c-src. Nature 385: 595-602.
82. Xu, X., Williams, J. W., Bremer, E. G., Finnegan, A. and Chong, A. S.-F. (1995) Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol.Chem. 270: 12398-12403.
83. Xu, X., Williams, J. W., Gong, H., Finnegan, A. and Chong, A. S.-F. (1996) Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem. Pharmacol. 52: 527-534.
84. Yamaki, H., Nakajima, M., Seimiya, H., Saya, H., Sugita, M. and Tsuruo, T. (1995) Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-myc expression by geldanamycin, an inhibitor of src tyrosine kinase. J. Antibiot. 48: 1021-1026.
85. Yokoyama, A., Okabe-Kado, J., Uehara, Y., Oki, T., Tomoyasu, S., Tsuruoka, N. and Honma, Y. (1996) Angelmicin B, a new inhibitor of oncogenic signal transduction, inhibits growth and induces myelomonocytic difterentiation of human myeloid leukemia HL-60 cells. Leuk. Res. 20: 491-497.
86. Zhen, X., Bonjour, J.-P. and Caverzasio, J. (1997) Platelet-derived growth factor stimulates sodium-dependent Pi transport in osteoblastic cells via phospholipase Cγ and phosphatidylinositol 3′-kinase. J. Bone Miner. Rev 12: 36-44.
87. Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., Lydon, N. B. and Traxler, P. (1996) (Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 6: 1221-1226.
88. Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T. and Lydon, N. B. (1997) Potent and selective inhibitors of the abl-kinase: phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 7: 187-192.